Suvorexant 20 mg + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Delirium in Old Age

Conditions

Delirium in Old Age

Trial Timeline

Jun 28, 2023 → Jul 7, 2025

NCT ID

NCT05733286

About Suvorexant 20 mg + Placebo

Suvorexant 20 mg + Placebo is a phase 2 stage product being developed by Merck for Delirium in Old Age. The current trial status is completed. This product is registered under clinical trial identifier NCT05733286. Target conditions include Delirium in Old Age.

What happened to similar drugs?

5 of 13 similar drugs in Delirium in Old Age were approved

Approved (5) Terminated (3) Active (6)

✅Rivastigmine + PlaceboNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ParecoxibPfizerApproved

✅Cyclopofol + PropofolHaisco Pharmaceutical GroupApproved

✅Dexmedetomidine Hydrochloride GroupBrain BiotechApproved

🔄Suvorexant + PlaceboMerckPhase 3

🔄Rivastigmine prevention of deliriumNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05733286	Phase 2	Completed	Jun 28, 2023	Jul 7, 2025	Delirium in Old Age
NCT04629547	Phase 2	Recruiting	May 25, 2022	May 1, 2026	Sleep

Competing Products

17 competing products in Delirium in Old Age

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Suvorexant + Placebo	Merck	Phase 3	40
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Rivastigmine Patch	Novartis	Approved	43
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	40
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17